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Background: N-methyl-D-aspartate receptors (NMDARs) are critical for neuronal development and synaptic
plasticity. Dysregulation of NMDARs is implicated in neuropsychiatric disorders. Native NMDARs are
heteromultimeric protein complexes consisting of NR1 and NR2 subunits. NR2 subunits (NR2A–D) are the major
determinants of the functional properties of NMDARs. Most research has focused on NR2A- and/or NR2B-containing
receptors. A recent study demonstrated that NR2C- and/or NR2D-containing NMDARs are the primary targets of
memantine, a drug that is widely prescribed to treat Alzheimer’s disease. Our laboratory demonstrated that
memantine prevents the loss of retinal ganglion cells (RGCs) in GLAST glutamate transporter knockout mice, a
model of normal tension glaucoma (NTG), suggesting that NR2D-containing receptors may be involved in RGC loss
in NTG.
Results: Here we demonstrate that NR2D deficiency attenuates RGC loss in GLAST-deficient mice. Furthermore,
Dock3, a guanine nucleotide exchange factor, binds to the NR2D C-terminal domain and reduces the surface
expression of NR2D, thereby protecting RGCs from excitotoxicity.
Conclusions: These results suggest that NR2D is involved in the degeneration of RGCs induced by excitotoxicity,
and that the interaction between NR2D and Dock3 may have a neuroprotective effect. These findings raise the
possibility that NR2D and Dock3 might be potential therapeutic targets for treating neurodegenerative diseases
such as Alzheimer’s disease and NTG.
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Glutamate is the major excitatory neurotransmitter in the
mammalian central nervous system (CNS) and plays an
essential role in neural development and information pro-
cessing through a variety of ionotropic (ligand-gated) and
metabotropic (G-protein–coupled) receptors [1]. However,
increased levels of glutamate results in extensive stimula-
tion of these receptors, which can eventually become
neurotoxic [2,3]. Overstimulation of N-methyl-D-aspartate* Correspondence: tanaka.aud@mri.tmd.ac.jp
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reproduction in any medium, provided the orreceptors (NMDARs) is implicated in many diseases, in-
cluding epilepsy, schizophrenia, and various neurodegen-
erative disorders [4-7].
Molecular cloning methods have identified multiple
NMDAR subunits, including NR1, a family of NR2 sub-
units (NR2A–NR2D), and two NR3 subunits (NR3A and
NR3B). Native NMDARs are heteromultimeric protein
complexes composed of NR1 and NR2 subunits, and in
some cases NR3 subunits. NR2 subunits are major determi-
nants of the functional properties of NMDARs, including
characteristics such as agonist affinity, deactivation kinetics,
single-channel conductance, Ca2+ permeability, and sensi-
tivity to Mg2+. Since NR2A- and NR2B-containing recep-
tors are highly expressed in the cortex, and NR2C- and
NR2D-containing receptors have low opening probabilitiesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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search has focused on NR2A- and/or NR2B-containing re-
ceptors [8-10].
Recently, it was demonstrated that Mg2+ regulates the
sensitivity of NMDARs to memantine, a drug that is
widely prescribed for the treatment of Alzheimer’s disease
[11]. In a physiological concentration (1 mM) of extracel-
lular Mg2+, memantine exerts a more potent blocking ef-
fect at NR2C/D subunits than NR2A/B subunits. These
findings suggest that NR2C- and/or NR2D-containing
NMDARs are likely to be the main targets of memantine.
In comparison with the NR2C subunit, NR2D is a particu-
larly interesting NMDAR subunit because it mediates the
mechanisms by which phencyclidine (PCP) induces loco-
motor hyperactivity in a novel environment, behaviors
thought to model positive symptoms of schizophrenia [12].
NR2D subunits are broadly expressed in the adult mam-
malian brain, including the hippocampus, cortex and ret-
ina, all of which are regions of the CNS thought to be
involved in Alzheimer’s disease, schizophrenia, and glau-
coma [8,13-15]. Previously, our laboratory demonstrated
that memantine prevented the loss of retinal ganglion
cells (RGCs) in glutamate aspartate transporter (GLAST)
knockout mice, a model of NTG [16], suggesting that
NR2D-containing receptors may be involved in RGC loss
in NTG. In the present study, we first investigated
whether NR2D is involved in the excitotoxic degeneration
of RGCs. Using yeast two-hybrid screening we identified
NR2D-interacting molecules that modulate the function
or localization of NR2D-containing NMDARs.Figure 1 NR2D deficiency prevents the loss of RGCs in GLAST-deficien
5 weeks. Scale bar: 50 μm. (B) Quantification of RGC number in WT, NR2D−
the GCL was counted in retinal sections from one ora serrata through theHere, we report that NR2D deficiency protects RGCs
from excitotoxicity. In addition, we identified dedicator of
cytokinesis 3 (Dock3) as a novel NR2D subunit interacting
protein, and showed that the interaction between NR2D
and Dock3 protects RGCs from excitotoxicity by reducing
the surface expression of NR2D.
Results
NR2D deficiency prevents RGC death in GLAST-deficient
mice
To determine whether NR2D is involved in RGC degener-
ation in GLAST-deficient mice, we examined the histo-
pathology of retinas from GLAST−/− and NR2D−/− mice.
As shown in Figure 1, the retinas of NR2D−/− mice
showed normal organization at 5 weeks. The cell number
in the ganglion cell layer (GCL) of NR2D−/− mice (494 ±
26) was not significantly different from that in wild-type
(WT) mice (514 ± 9), whereas the cell number in the GCL
of GLAST−/− mice was significantly less (307 ± 6) than that
in WT. However, in GLAST−/− NR2D−/− double-knockout
mice, the number of GCL cells was significantly higher
(401 ± 10) than that in GLAST−/− mice, although it was
still lower than that in WT and NR2D−/− mice. These re-
sults suggest that NR2D deficiency protects against the
loss of RGCs in GLAST-deficient mice.
NR2D deficiency prevents NMDA-induced-excitotoxic
retinal cell death
In GLAST-deficient mice, both excitotoxicity and oxidative
stress contribute to RGC degeneration [16]. To investigatet mice. (A) Hematoxylin and eosin staining of retinal sections at
/−, GLAST−/−, and GLAST−/−/NR2D−/− mice. The number of neurons in
optic nerve to the other ora serrata. n = 5 per group. **p < 0.01.
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resulting from NMDA-induced excitotoxicity, we used
TUNEL assay to examine the retinas of mice 24 h after an
intravitreal injection of NMDA. No TUNEL-positive cells
were detected in the controls or NR2D−/− mice after in-
jection of phosphate-buffered saline (PBS) (Figure 2A),
whereas a number of TUNEL-positive cells were observed
in the GCL and inner nuclear layer (INL) after injection of
NMDA (Figure 2B). NR2D deficiency significantly reduced
the mean number of TUNEL-positive cells in the GCL, but
not in the INL (Figure 2C, D). These results suggest that
NR2D deficiency protects against excitotoxicity-induced
retinal cell death in the GCL.
Identification of Dock3 as an NR2D-interacting molecule
Multiple studies show that protein-protein interactions in-
volving the intracellular C-terminal domains of NMDARs
control the function and localization of these receptors
[17-20]. To identify novel binding partners of the NR2D
subunit, we performed a yeast two-hybrid screening of a
mouse brain cDNA library using the C-terminal domain
of NR2D (residues 895–1323) as bait (Figure 3A). Two of
the 77 clones initially identified as interacting proteins
encoded the Dock homology region 2 (DHR-2) domain
(Figure 3B) of dedicator of cytokinesis 3 (Dock3), also
known as modifier of cell adhesion (MOCA), which is spe-
cifically expressed in the CNS [21]. To investigate whether
NR2D and Dock3 also interact in mammalian cells, hu-
man embryonic kidney (HEK) 293 T cells were transfectedFigure 2 NR2D deficiency prevents NMDA-induced-excitotoxic retinal
mice 24 hr after PBS and NMDA injection. Arrowheads in B indicate TUNEL
positive cells in the GCL (C) and INL (D). n = 5 per group. **p < 0.01.with expression plasmids encoding a Myc-tagged Dock3
interaction domain (amino acids 796–1154) and/or the
NR2D C-terminus (amino acids 895–1323) carrying an
EGFP tag. Protein lysates were prepared from the
transfected cells for co-immunoprecipitation analyses.
Western blots of anti-EGFP immunoprecipitates with
an anti-Myc antibody revealed that the Dock3 inter-
action domain co-precipitated with the EGFP-tagged
NR2D C-terminus only when both proteins were expressed
(Figure 3C, left panel). Conversely, the NR2D C-terminus
was present in anti-Myc immunoprecipitates of Dock3
interaction domain (Figure 3C, right panel), indicating that
Dock3 was associated with the NR2D C-terminus in heter-
ologous HEK293T cells.
To determine whether Dock3 also interacted with NR2D
in the retina, anti-NR2D immunoprecipitates from retina
lysates were probed with an anti-Dock3 antibody. However,
Dock3 was not detected in anti-NR2D immunoprecipitates,
likely due to the low expression level of NR2D. Therefore,
we performed co-immunoprecipitations using brain ho-
mogenates from mice at embryonic day 18, when the ex-
pression level of NR2D is high. The data clearly showed
that Dock3 co-immunoprecipitated with NR2D (Figure 4A),
and reciprocal co-immunoprecipitation experiments
(Figure 4B) confirmed that Dock3 associated with NR2D
in the embryonic brain.
Taken together, these results demonstrated that Dock3
effectively interacts with NR2D subunits in both cul-
tured human cells and mouse embryonic brain.cell death. (A and B) TUNEL analysis of retinas of WT and NR2D−/−
-positive cells. Scale bar: 50 μm. (C and D) The number of TUNEL-
Figure 3 Identification of Dock3 as an NR2D-interacting molecule. (A) Schematic diagram of NR2D and a probe used for yeast two-hybrid
screening. M1–M4 indicates the transmembrane regions. The numbers refer to the amino-acid positions of NR2D. (B) Schematic diagram of
Dock3. The selected interaction domain (SID) corresponds to the minimal region common to all fragments identified by yeast two-hybrid
screening. The numbers indicate the amino-acid positions within Dock3. DHR-1, Dock homology region 1; DHR-2, dock homology region 2; PRR,
proline-rich region. (C) The interaction between NR2D and Dock3 in HEK293T cells. HEK293T cells were transfected with plasmids encoding the
SID of Dock3 (Myc-Dock3 SID) and EGFP-tagged NR2D C-terminus (EGFP-NR2D CT). Lysates of transfected cells were immunoprecipitated (IP) with
anti-GFP (left panel) or anti-Myc antibodies (right panel). Immune complexes were detected by Western blotting with anti-GFP or anti-Myc
antibodies. In lanes 1–3, 1/10th volumes of the lysates used for immunoprecipitation were loaded for TCL samples. IB, Immunoblotting.
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Because NR2D is involved in excitotoxic degeneration
of RGCs, we examined the distribution of Dock3 and
NR2D expression in the mouse retina. Immunohisto-
chemical analysis showed that Dock3 is expressed in theFigure 4 Interaction of Dock3 with NR2D in brain. (A) Identification
of NR2D in Dock3 immunoprecipitates from WT, but not NR2D−/−
embryonic-brain homogenates. (B) Identification of Dock3 in NR2D
immunoprecipitates from WT, but not NR2D−/− embryonic-brain
homogenates. The immunoprecipitates and brain lysates were
subjected to immunoblotting with anti-NR2D and anti-Dock3
antibodies. IP, immunoprecipitation; IB, immunoblotting.RGCs (Figure 5A). In addition, co-labeling with anti-
NR2D antibodies revealed that Dock3 colocalizes with
NR2D in these cells (Figure 5B, C). These data suggest
that co-expression of NR2D and Dock3 occurs not only in
the embryonic brain, but also in the GCL of the retina.
Overexpression of Dock3 inhibits glutamate-induced
intracellular Ca2+ elevation and prevents glutamate-
induced apoptosis in RGCs
Next, we examined the functional consequences of the
interaction between NR2D and Dock3, using primary
cultures of RGCs. Previously, we reported that glutamate-
induced Ca2+ elevation and apoptosis in RGCs are medi-
ated by NMDARs [22]. Therefore, we examined the effects
of overexpressing Dock3 on glutamate-induced Ca2+ ele-
vation and apoptosis in cultured RGCs. Fluorescence-ratio
images, displayed in pseudocolor in Figure 6A, demon-
strated that glutamate markedly increased the intracellular
Ca2+ concentration in RGCs from WT mice. Over-
expression of Dock3 significantly inhibited glutamate-
induced intracellular Ca2+ elevation in RGCs (Figure 6A,
B). Because an increase in intracellular Ca2+ in RGCs
mediated by NMDARs is a key step in initiating apop-
tosis [22,23], we next examined the neuroprotective ef-
fect of Dock3 on RGCs. Whereas 300 μM glutamate
induced apoptosis in RGCs from WT mice (Figure 6C),
overexpression of Dock3 significantly inhibited glutamate-
induced apoptosis (Figure 6C). Together, these find-
ings demonstrate that overexpression of Dock3
Figure 5 Co-localization of NR2D and Dock3 in the mouse retina. Double-labeling experiments were carried out on mouse retina sections
(A-C). Dock3 (A) is red and NR2D (B) is green. Dock3 co-localized with NR2D in RGCs shown in the overlay panel (C) (arrowheads). Scale bar:
50 μm. (D) No NR2D immunoreactivity (green) was detected in retinas from NR2D−/− mice. Nuclei are counterstained with DAPI (blue). Scale bar:
50 μm. IPL, inner plexiform layer.
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and prevents glutamate-induced apoptosis in RGCs,
suggesting that the interaction between NR2D and
Dock3 suppresses the function of NR2D-containing
NMDARs.Figure 6 Overexpression of Dock3 inhibits glutamate-induced intrace
in RGCs. (A) RGCs from WT or Dock3-transgenic (Tg) mice were labeled w
(Glu) was added. Fluorescence-ratio images are displayed in pseudocolor, a
Pseudocoloring represents ratios between 0 and 2, corresponding to 1, wh
stimulation. Left and right panels show ratio images for WT and Dock3-Tg,
expressed as ΔF/F0, where F0 is the basal fluorescence intensity before Glu
SE from eight independent experiments. (C) Fragmented or shrunken nucl
glutamate (Glu) treatment. **p < 0.0001 for WT Glu vs. Dock3-Tg Glu. WT, w
transfected with NR1 and NR2D with (Dock3+) or without Dock3 (Dock3-).
immunoprecipitated with streptavidin beads and probed with NR2D antibo
experiments that yielded similar results. (E) Relative ratio of biotinylated pro
independent experiments.Dock3 suppresses the surface expression of NR2D
Because NMDARs undergo regulated endocytosis [24-26],
overexpression of Dock3 may reduce glutamate-induced
Ca2+ elevation and apoptosis in RGCs by reducing the
number of NMDARs on the cell surface. To investigatellular Ca2+ elevation and prevents glutamate-induced apoptosis
ith Fluo-8 acetoxymethyl ester for 30 min, and then 300 μM glutamate
s indicated by the color bar on the right side of the images.
ich is defined as the basal fluorescence intensities before Glu
respectively. Scale bar: 100 μm. (B) Changes in Fluo-8 fluorescence are
stimulation. Glu was added as indicated. Data represent the mean ±
ei were detected by Hoechst staining 24 hr after control (HBSS) or
ild-type mice; Dock3-Tg, Dock3 transgenic mice. (D) N2A cells were
Surface proteins were biotinylated using sulfo-NHS-SS-biotin,
dies. Data are from a single experiment, which is representative of five
tein to total protein. *p < 0.05. Data represent the mean ± SE from five
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NR2D, we used N2A neuroblastoma cells. N2A cells were
transfected with expression plasmids encoding NR1 and
NR2D, with or without a plasmid harboring the full-length
Dock3 cDNA. Cell-surface receptors were then quantified
using a biotinylation assay. As shown in Figure 6D and E,
the number of biotinylated NR2D subunits significantly
decreased upon co-expression of Dock3, however, no
changes was observed in the total amount of NR2D. These
results suggest that Dock3 suppresses the surface expres-
sion of NR2D-containing NMDARs, thereby inhibiting
glutamate-induced Ca2+ elevation and apoptosis in RGCs.Discussion
In the present study, we show that NR2D is involved in
the progressive loss of RGCs in GLAST-deficient mice,
an animal model of NTG. In addition, we identify Dock3
as a novel NR2D-interacting protein and show that the
interaction between NR2D and Dock3 protects RGCs
from excitotxicity by reducing the surface expression of
NR2D.
This is the first direct in vivo evidence of NR2D-
NMDAR-mediated excitotoxicity in the context of glau-
coma. In GLAST−/− mice, NR2D deficiency only partially
prevented loss of RGCs, whereas inhibition of NMDARs
with memantine almost completely prevented RGC loss
[16]. This may be due to the involvement of other NR2
subunits in RGC degeneration, especially the NR2C sub-
unit, given that NR2C-containing NMDARs are expressed
in RGCs [15] and are the targets of therapeutic meman-
tine activity [11]. NR2D deficiency prevented NMDA-
induced-excitotoxic retinal cell death specifically in GCL,
but not in INL. This can be explained by the lower expres-
sion level of NR2D in neurons of INL compared with
those in GCL and by the contribution of other NR2 sub-
units to NMDA-induced cell death in INL.
Considering the high frequency of glaucoma in
Alzheimer’s disease patients [27], common mechanisms
such as NR2D-NMDAR-mediated excitotoxicity might
contribute to both diseases. In addition, NR2D mediates
the capacity of PCP to induce locomotor hyperactivity in a
novel environment, behavior that is thought to model
positive symptoms in schizophrenia [12]. The genomic re-
gion that contains the NR2D gene locus has also been sug-
gested to contribute to susceptibility to schizophrenia in a
Japanese population [28]. NR2D is expressed in the adult
mammalian brain, including the hippocampus, cortex,
thalamus, and retina, all of which are CNS regions
thought to be involved in Alzheimer’s disease, schizophre-
nia, and glaucoma. Taken together, these findings suggest
that NR2D may play roles in various neuropsychiatric
diseases, including glaucoma, Alzheimer’s disease, and
schizophrenia, and may be a target for the development ofnovel drugs for the treatment of these neuropsychiatric
diseases.
Multiple studies show that protein-protein interactions
occurring at the intracellular C-terminal domains of
NMDARs control the function and localization of these
receptors. Whereas numerous proteins that interact with
NR2A and NR2B have been identified [20,29,30], few
directly interact with the NR2D subunit. The Abl tyro-
sine kinase is reported to interact directly with NR2D,
but this interaction has no direct effect on NR2D func-
tion [31].
In the present study, we identified Dock3 as a novel
NR2D-interacting protein. Dock3 was first identified as
a presenilin (PS)-binding protein (PBP) [21] expressed in
neurons and the testis, and is involved in cell adhesion
and neurite outgrowth [32]. Dock3 may be linked to the
pathogenesis of Alzheimer’s disease: it is absent from the
soluble fraction of samples taken from Alzheimer’s dis-
ease brains [21], accumulates in neurofibrillary tangles
[33], and regulates Aβ secretion [34]. Consistent with
this hypothesis, deletion of Dock3 results in axonal de-
generation and sensorimotor impairments [35]. Previously,
we showed that overexpression of Dock3 induces optic
nerve regeneration following injury [36]. In addition, we
showed the role of Dock3 in glutamate-induced Ca2+ ele-
vation and apoptosis of RGCs. In primary cultured RGCs,
NMDARs contribute to Ca2+ elevation and apoptosis in-
duced by 300 μM glutamate [22]. Overexpression of
Dock3 significantly inhibited these glutamate-induced re-
sponses. Considering the direct interaction between
Dock3 and NR2D, reflected in their co-localization, and
the role of NR2D in NMDA-induced retinal cell death,
these results suggest that Dock3 may play an important
role in protecting RGCs from excitotoxicity through
modulation of NR2D function.
Further mechanistic insights into the inhibition of
glutamate-induced Ca2+ elevation and apoptosis of
RGCs by overexpression of Dock3 were gained by
conducting biochemical analyses of the surface expres-
sion of NR2D. Co-expression of Dock3 suppressed the
expression of NR2D on the surface of the plasma
membrane. Although further studies are required to
clarify the mechanism by which Dock3 expression re-
duces the surface expression of NR2D, we can suggest
two possible explanations. The first is that Dock3
could activate Rac1; activated Rac1 may then reduce
the surface expression of NR2D by promoting endo-
cytosis, similar to Kir2.1 channels [37]. The second
possible explanation is that Dock3 interacts with both
Fyn [36] and NR2D; Fyn may then regulate the surface
expression of NR2D through tyrosine phosphorylation.
The NR2D protein is developmentally regulated by
tyrosine phosphorylation in vivo, suggesting that tyro-
sine phosphorylation may be important for regulating
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lian CNS [38].
Conclusions
We show here that NR2D is involved in excitotoxic degen-
eration of retinal cells and that Dock3 is a novel NR2D-
interacting protein. Moreover, the interaction between
NR2D and Dock3 protects RGCs from excitotoxicity by
reducing the surface expression of NR2D. Identification
of chemical compounds that can increase the expression
of Dock3, or otherwise reduce the surface expression of
NR2D, might have therapeutic benefit for the treatment of




GLAST and NR2D mutant mice were described previ-
ously [39,40]. Double-knockout mice (GLAST−/−/NR2D−/−)
and homozygous GLAST-knockout mice (GLAST−/−)
were obtained by crossing double heterozygous mice
(GLAST+/−/NR2D+/−). The homozygous NR2D-knockout
mice (NR2D−/−) were obtained by crossing heterozygous
mice (NR2D+/−). The genotypes of the mutant mice were
determined as described previously [39,40]. Dock3 trans-
genic mice overexpress wild-type Dock3 under the control
of the actin promoter [36]. In all experiments, age-
matched WTand GLAST−/− littermate controls were used.
All mice were of the C57BL/6 J genetic background,
and all animal procedures were approved by the Animal
Committee of Tokyo Medical and Dental University
(0130166C).
Histological analysis
Mice were deeply anesthetized by diethyl ether. Eyes from
mice at postnatal day 35 (P35) were enucleated, fixed in
Davidson’s solution fixative [41] overnight at 4°C, and
dehydrated in 70% ethanol for three days at 4°C. The fixed
eyes were then embedded in paraffin wax. Sections (7-μm
thickness) of embedded retinal specimens were cut and
stained with hematoxylin and eosin. The number of neu-
rons in the GCL was counted from one ora serrate,
through the optic nerve, to the other ora serrata. The aver-
age number of neurons in the GCL per eye was calculated
from three sections of each retina.
Intravitreal injection of NMDA
WT and NR2D−/− mice (5 weeks old) were anesthetized
by intraperitoneal injection of 50 mg/kg sodium pento-
barbital, and their pupils were dilated with tropicamide.
A single 2-μl injection of 20 mM NMDA in 0.1 M PBS
(pH 7.40) was administered intravitreally into the right
eye of each mouse, thereby delivering a dose of 40 nmol
of NMDA. The same volume of PBS was administeredto the contralateral (left) eye as control. To avoid lens
injury, injections were performed under a stereomicro-
scope through a 32-gauge needle (Dentronics) connected
to a 10-μl Hamilton syringe (Hamilton); the needle was
inserted approximately 1 mm behind the corneal limbus.TUNEL assay
Twenty-four hours after the NMDA or PBS injection, eyes
were enucleated, fixed in Davidson fixative overnight at
4°C, embedded in paraffin, and sectioned (5-μm thick-
ness). Apoptotic cells were labeled using the DeadEnd
Fluorometric TUNEL (terminal deoxynucleotidyl transfer-
ase dUTP nick end labeling) System (Promega) according
to the manufacturer's instructions. TUNEL-positive cells
in GCL and INL were counted manually under a micro-
scope. The average number of TUNEL-positive cells per
eye was calculated for three sections of each retina.Yeast two-hybrid screening
Yeast two-hybrid screening was performed by Hybrigenics
Services, S.A.S., Paris, France. The coding sequence for
the cytoplasmic region (aa 895–1323) of mouse NR2D
(GenBank accession number gi: 144922605) was PCR-
amplified and cloned into pB27 as a C-terminal fusion to
LexA. The resulting plasmid, pB27 (N-LexA-NR2D-C),
was used as a bait to screen a random-primed mouse adult
brain cDNA library cloned into vector pP6. The bait
strain/prey strain mating was spread on a medium lacking
tryptophan, leucine, and histidine, and supplemented with
5 mM 3-aminotriazole to overcome bait auto-activation.
A total of 357 positive clones were obtained out of 82 mil-
lion interactions tested. The prey fragments of the positive
clones were amplified by PCR and sequenced at their 5’
and 3’ junctions. The resulting sequences were used to
identify the corresponding interacting proteins in the
GenBank database (NCBI).DNA constructs
Full-length mouse NR1 and NR2D cDNAs were amplified
from vectors described previously [42,43] and subcloned
into vector pEGFP C1 (Clontech), such that the NR2D
protein was fused in frame with the C-terminal EGFP epi-
tope. A similar plasmid was constructed for expression of
the region containing the NR2D CT (aa 895–1323). The
plasmid encoding mouse Dock3 cDNA (GenBank acces-
sion number gi: 148277095) was described previously [36].
The selected interacting domain (SID) of Dock3 was amp-
lified by PCR and subcloned into vector pEF1/myc-His A
(Invitrogen) such that the Dock3 protein was fused in
frame with the N-terminal myc and His epitopes. All ex-
pression plasmids were confirmed by DNA sequencing.
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HEK 293 T cells were cultured on 10-cm plates in
Dulbecco’s modified Eagle’s medium (Sigma), supple-
mented with 10% fetal bovine serum (GIBCO) at 37°C in
atmosphere containing 5% CO2. When the cells reached
70% confluence, they were transiently transfected with
cDNA constructs (up to 6 μg total) using the GeneJuice
transfection reagent (Novagen).
Immunoprecipitation and immunoblotting
Cells were harvested 48 h after transfection and resus-
pended in cold lysis buffer (50 mM Tris–HCl, 1% Nonidet
P-40, 5 mM EDTA, 150 mM NaCl, 0.5% Na-deoxycholate,
1 mM MgCl2, 1 mM DTT, 1 mM Na3VO4, 1 mM
NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), and
Complete Protease Inhibitor Cocktail [Roche]). Samples
were left on ice for 30 min and sonicated briefly. The
insoluble fraction was removed by centrifugation at
15,000 rpm for 15 min. Protein concentration was deter-
mined using BCA Protein Assay kit (Sigma-Aldrich). Total
cell lysates (TCLs) were boiled in the presence of 2× sam-
ple buffer. Immunoprecipitation was performed with 50 μl
of anti-Myc magnetic beads (clone PL14; MBL), anti-GFP
magnetic beads (clone RQ2; MBL), and 400 μg of cell
homogenate according to the manufacturer’s protocol.
Immunoprecipitates and TCL were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred onto polyvinylidene difluoride (PVDF, Millipore)
membranes. The membranes were blocked with 10% skim
milk/PBST (PBS containing 0.05% Tween 20) solution for
1 h at room temperature, and then treated with primary
antibodies. The following antibodies were used for the
blots: anti–Myc-tag rabbit polyclonal antibody (1:1000;
MBL) and anti-GFP rabbit polyclonal Living Colors Av
peptide antibody (1:100; Clontech Laboratories). After 1 h
at room temperature, the membrane was washed three
times in PBST for 30 min and incubated for 1 h in
horseradish peroxidase (HRP)-conjugated second antibody
(1:10,000; Jackson ImmunoResearch Laboratories, Inc.).
For in vivo immunoprecipitation, 90 mg of brain tissue
was collected from mice at embryonic day 18 and homoge-
nized using a POLYTRON PT 1200E homogenizer
(Kinematica AG) in 500 ul cold lysis buffer (300 mM NaCl,
5 mM Tris-Cl [pH 7.5], 0.5% Triton X-100, and Complete
Protease Inhibitor Cocktail). Co-immunoprecipitation was
performed according to the method previously described
[44] with some modifications. Briefly, the sample was left
on ice for 1 h, spun at 10,000 g for 20 min at 4°C, and the
supernatant was collected, and the protein concentration
was determined using BCA Protein Assay kit. NR2D anti-
body [45] (1 μg) and Dock3 antibody [46] (0.5 μg) were
added to 500 μl of pre-cleared lysate and incubated at 4°C
overnight. Protein G Sepharose (50 μl) was then added to
collect the immunoprecipitate. Samples were incubated at4°C for 2 h and centrifuged at 1,000 g for 1 min, and
supernatant was removed. The precipitate was washed
three times with 1 ml of lysis buffer. Each sample was
diluted with 50 μl of 2× sample buffer and run on an
SDS polyacrylamide gel (7.5%); an equal volume (20 μl)
of each sample was loaded onto the gel. Separated proteins
were transferred to PVDF membranes. The membranes
were then incubated with an anti-NR2D guinea-pig poly-
clonal antibody (1:1000) and an anti-Dock3 rabbit poly-
clonal antibody (1:1000) at 4°C overnight. The membrane
was washed three times in TBST (TBS containing 0.05%
Tween 20) for 30 min and incubated for 1 h with an
HRP-conjugated secondary antibody (1:5,000–1:10,000).
SuperSignal West Femto Maximum Sensitivity Sub-
strate (Thermo Scientific) was used to visualize the im-
munoreactive proteins.
Immunohistochemistry
Mice were deeply anesthetized by diethyl ether and per-
fused with 0.1 M PBS and then with 4% PFA in 0.1 M PB.
Eyes were immediately enucleated and immersed in the
same fixative for 2 hours at 4°C, followed by immersion in
a sucrose solution (30% in PB) overnight at 4°C. Eyes were
embedded in OCT compound (Sakura Finetechnical Co.
Ltd) and frozen on dry ice. The eyes were sectioned
(10-μm thickness) using a cryostat. After washing in
PBS, the sections were blocked with 5% normal horse
serum diluted in PBS with 0.2% Triton X-100 for 30 mi-
nutes at room temperature. Sections were incubated
overnight at 4°C with a goat polyclonal antibody against
NR2D (1:50; Santa Cruz Biotechnology, INC) and a
rabbit polyclonal antibody against Dock3 (1:100). Sec-
tions were then incubated with secondary antibodies
against goat and rabbit IgG (Alexa Furo 488, 1:1000;
Alexa Furo 568, 1:500; both from Molecular Probes) for
1 h at room temperature. After a final rinse in PBS, the
sections were cover-slipped with Fluoromount (Diagnostic
BioSystems). Images were recorded with an LSM-510
META confocal laser microscope (Carl Zeiss).
Primary culture of mouse retinal ganglion cells
C57BL/6 J or Dock3-Tg mice (7–10 days old) were used
for primary culture of RGCs according to Winzeler
et al. [47] with some modifications. Briefly, retinae
were digested with papain (16.5 units/ml) for 45 min at
37°C, triturated in Minimum Essential Medium (MEM;
Invitrogen) containing 0.15% trypsin inhibitor (Roche
Applied Science), and then triturated again in MEM
containing 1% trypsin inhibitor. The cell suspension
was incubated on a first panning plate (150 mm Petri
dish) coated with Bandeiraea lectin I (L-1100; Vector
Laboratories, Inc.) for 10 min at room temperature.
Non-adherent cells were incubated for 45 min on a second
panning plate (100 mm Petri dish) coated with goat anti-
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Laboratories, Inc.) and mouse anti-mouse Thy1.2 IgM anti-
bodies (MCA02R; AbD Serotec, Oxford, UK). The panning
plate was washed with PBS, and adherent RGCs were re-
leased by treatment with 0.125% trypsin for 10 min at 37°C.
The RGC suspension was mixed with 30% fetal bovine
serum and centrifuged at 200 g for 10 min. RGCs were
suspended in medium containing 1 mM glutamine, 5 μg/ml
insulin, 60 μg/ml N-acetylcysteine, 62 ng/ml proges-
terone, 16 μg/ml putrescine, 40 ng/ml sodium selenite,
0.1 mg/ml BSA, 40 ng/ml triiodothyronine, 0.1 mg/ml
transferrin, 1 mM sodium pyruvate, 2% B27 supplement
(Invitrogen), 10 μM forskolin (Sigma), 50 ng/ml brain-
derived neurotrophic factor (BDNF; PeproTech, Rocky
Hill, NJ), 50 ng/ml ciliary neurotrophic factor (CNTF;
PeproTech), and 50 ng/ml basic fibroblast growth factor
(bFGF; PeproTech) in Neurobasal medium (Invitrogen).
Ninety-six–well culture plates were coated with poly-D-
lysine (Sigma) and laminin (Sigma) and mouse RGCs
were plated at a density of 4,000 cells/well (or 4,000
cells/culture insert for μ-dishes (ibidi)) and cultured for
at least 10 days before the experiments.
Induction and detection of apoptosis induced by
glutamate
RGCs were washed twice (15-min incubation, ×2) with
Hank’s Balanced Salt Solution (HBSS; Invitrogen) con-
taining 2.4 mM CaCl2 and 20 mM HEPES without magne-
sium. Subsequently, RGCs were incubated for 2 h at 37°C
with or without 300 μM glutamate and 10 μM glycine
(a co-activator of NMDARs) in HBSS containing 2.4 mM
CaCl2 and 20 mM HEPES without magnesium. After
HBSS or glutamate treatment, RGCs were cultured for
22 h at 37°C in the same medium to culture the RGCs,
but without forskolin, BDNF, CNTF, and bFGF. To detect
apoptosis using Hoechst 33342 (Dojindo), RGCs were
washed once with PBS and incubated with 1 μg/ml
Hoechst 33342 for 15 min at room temperature. Fluores-
cent images were randomly taken (four images/well) using
an Olympus IX71 fluorescence microscope. For each
treatment, at least eight images were taken from two wells
of a 96-well plate. Fragmented or shrunken nuclei stained
with Hoechst dye were deemed apoptotic, and neurons
with round and smooth nuclei were counted as healthy.
More than 200 neurons for each treatment were counted
by a researcher blinded to the identity of the samples.
Measurement of intracellular calcium
Mouse RGCs were incubated for 30 min at 37°C in cul-
ture medium with 3 μM Fluo-8 acetoxymethyl ester
(AAT Bioquest). Cells were washed twice (15-min incu-
bation, ×2) with HBSS containing 2.4 mM CaCl2 and
20 mM HEPES without magnesium, then stimulated
with 300 μM glutamate and 10 μM glycine. Fluorescenceimages were acquired every 500 msec using an ORCA-
R2 digital CCD camera (Hamamatsu Photonics) and an-
alyzed using the MetaFluor fluorescence-ratio imaging
software (Molecular Devices).
Surface-biotinylation assay
Neuro 2A cells were plated at a density of 2 × 105/well in
6-well plates and cultured in 95% air/5% CO2 at 37°C. The
cells were transiently co-transfected with the cDNAs en-
coding NR1 and NR2D with (Dock3+) or without (Dock3-)
Dock3. Forty-eight hours after transfection, cells were incu-
bated in PBS containing 1.5 mg/ml Sulfo-NHS-SS-biotin
(Pierce) for 20 min at 4°C. Surface biotinylation was
stopped by removing that solution and incubating the cells
in 10 mM ice-cold glycine in PBS for 20 min. Cells were
rinsed twice in PBS and then lysed in 200 μl PBS with
Complete Protease Inhibitor Cocktail, 0.1% SDS, and 1%
Triton X-100. A fraction (15%, 30 μl) of the cell lysate was
removed to measure total protein concentration and for
total input; the remaining 85% (170 μl) of the cell lysate
was incubated with 70 μl of 50% avidin-agarose (Sigma)
overnight at 4°C. After washing three times with lysis buffer,
bound proteins were resuspended in 30 μl of 2× sample
buffer and boiled. Samples were analyzed by SDS-PAGE
followed by Western blotting using anti-NR2D guinea-pig
polyclonal antibody (1:1000). The data were quantified by
measuring the ratios between intensities of the biotinylated
and total NR2D bands using the Image Lab software (Bio-
Rad). Surface/total ratios from the Dock3- control were
assigned a value of 1. Ratios of the Dock3+ groups were
expressed relative to the controls and averaged.
Statistical analysis
All data are expressed as mean ± S.E. Statistical analyses
were conducted using Student's t-test for comparison
between two samples, or one-way ANOVA followed by
Bonferroni’s test for multiple comparisons, using the
SPSS 17.0 software package. P values < 0.05 were consid-
ered statistically significant.
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